Current Psychiatry Reports

, 15:385 | Cite as

Globalization and Cognitive Enhancement: Emerging Social and Ethical Challenges for ADHD Clinicians

  • Ilina Singh
  • Angela M. Filipe
  • Imre Bard
  • Meredith Bergey
  • Lauren Baker
Attention-Deficit Disorder (R Bussing, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Attention-Deficit Disorder

Abstract

Globalization of ADHD and the rise of cognitive enhancement have raised fresh concerns about the validity of ADHD diagnosis and the ethics of stimulant drug treatment. We review the literature on these two emerging phenomena, with a focus on the corresponding social, scientific and ethical debates over the universality of ADHD and the use of stimulant drug treatments in a global population of children and adolescents. Drawing on this literature, we reflect on the importance of ethically informed, ecologically sensitive clinical practices in relation to ADHD diagnosis and treatment.

Keywords

Attention deficit hyperactivity disorder ADHD Stimulants Ritalin Adderall Globalization Diagnosis Treatment Medicalization Prevalence Global mental health Cognitive enhancement Culture Ecology Hyperactivity International Addiction Diversion Diagnostic criteria Clinical practice Ethics Psychiatry 

References

Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Conrad P. Identifying hyperactive children: The medicalization of deviant behaviour. Lexington, MA: Lexington Books; 1976.Google Scholar
  2. 2.
    Conrad P. The medicalization of society: On the transformation of human conditions into treatable disorders. Baltimore, Johns Hopkins UP;2007.Google Scholar
  3. 3.
    Shrag P, Divoky D. The myth of the hyperactive child and other means of child control. New York: Pantheon;1975.Google Scholar
  4. 4.
    Barkley R. Issues in the diagnosis of attention-deficit/hyperactivity disorder in children. Brain Dev. 2003;25:77–83.PubMedCrossRefGoogle Scholar
  5. 5.
    Malacrida C. Medicalization, Ambivalence and Social Control: Mothers’ Descriptions of Educators and ADD/ADHD. Health (London). 2004;8(1):61–80.CrossRefGoogle Scholar
  6. 6.
    Horwitz A. Creating mental illness. Chicago: Chicago UP; 2002.Google Scholar
  7. 7.
    Sonuga-Barke EJ, Schlotz W, Kreppner J. Differentiating developmental trajectories for conduct, emotion and peer problems following early deprivation. Monographs of the Society for Research in Child Development. 2010;75:102–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Parens E, Johnson J. Facts, values and Attention Deficit Hyperactivity Disorder (ADHD): an update on the controversies. Child Adolesc Psychiatry Ment Health. 2009;3:1. doi:10.1186/1753-2000-3-1.PubMedCrossRefGoogle Scholar
  9. 9.
    Mayes R, Bagwell C, Erkulwater J. ADHD and the Rise in Stimulant Use Among Children. Harv Rev Psychiatry. 2008;16:151–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Singh I. Beyond Polemics: Science and ethics of ADHD. Nat Rev Neurosci. 2008;9(12):957–64.PubMedCrossRefGoogle Scholar
  11. 11.
    • Parens E. On good and bad forms of medicalization. Bioethics. 2013;27(1):28–35. An important development in the medicalization debates that moves the concept on from older versions into interesting and useful new territory.PubMedCrossRefGoogle Scholar
  12. 12.
    Singh I. Human development, nature and nurture: Working beyond the divide. BioSocieties. 2012. doi:10.1057/biosoc.2012.20.Google Scholar
  13. 13.
    Worthman CM, Protsky PM, Schechter DS, Cummings CA. Formative experiences: The interaction of caregiving, culture and developmental biology. Cambridge, UK: CUP; 2010.CrossRefGoogle Scholar
  14. 14.
    Layard R, Dunn J. A Good Childhood. London: Penguin; 2009.Google Scholar
  15. 15.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM) – 5. Virginia, USA: American Psychiatric Publishing; 2013.Google Scholar
  16. 16.
    Centres for Disease Control and Prevention (CDC). Mental health surveillance among children- United States, 2005–2011. Atlanta, GA: US Dept of Health and Human Services; 2013.Google Scholar
  17. 17.
    Schwarz A, Cohen S. A.D.H.D. Seen in 11% of U.S. Children as Diagnoses Rise. The New York Times March. 2013(31).Google Scholar
  18. 18.
    Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff. 2007;26:450–7.CrossRefGoogle Scholar
  19. 19.
    Cornejo JW, Osio O, Sanchez Y, et al. Prevalence of attention deficit hyperactivity disorder in Columbian children and teenagers. Rev Neurol. 2005;40(12):716–22 [in Spanish].PubMedGoogle Scholar
  20. 20.
    Pineda D, Ardila A, Rosselli M, et al. Prevalence of attention—deficit/hyperactivity disorder symptoms in 4–17 year old children in the general population. J Abnorm Child Psychol. 1999;27(6):455–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Pino P, Mojarro-Praxedes M. Hyperkinetic D disorders: double-phase epidemiological study of a population from Sevilla. An Psiquiatria. 2001;17(6):265–70 [in Spanish].Google Scholar
  22. 22.
    Catalá-López F, Peiró S, Ridao M, Sanfélix-Gimeno G, Gènova-Maleras R, Catalá MA. Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies. BMC Psychiatry. 2012; doi: 10.1186/1471-244X-12-168
  23. 23.
    Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Polanczyk G, Jensen P. Epidemiological considerations in Attention Deficit Hyperactivity Disorder: A review and update. Child Adolesc Psychiatric Clin N Am. 2008;17:245–60.CrossRefGoogle Scholar
  25. 25.
    Gomez R, Harvey J, Quick C, et al. DSM-IV AD/HD: confirmatory factor models, prevalence, and gender and age differences based on parent and teacher ratings of Australian primary school children. J Child Psychol Psychiatry. 1999;40(2):265–74.PubMedCrossRefGoogle Scholar
  26. 26.
    Levy F, Hay DC, McStephen M, et al. Attention deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Child Adolesc Psychiatry. 1997;36(6):737–44.CrossRefGoogle Scholar
  27. 27.
    Hinshaw SP, Scheffler RM, Fulton BD, Aase H, Banaschewski T, Cheng W, Mattos P, Holte A, Levy F, Sadeh A, Sergeant JA, Taylor E, Weiss MD. International Variation in Treatment Procedures for ADHD: Social Context and Recent Trends. Psychiatr Serv. 2011:62(5). http://ps.psychiatryonline.org/article.aspx?articleID=116182
  28. 28.
    INCB. Psychotropic Substances: Statistics for 2011. International Narcotics Control Board Report. 2012. http://www.incb.org/documents/Psychotropics/technical-publications/2012/en/Eng_2012_PUBlication.pdf. Accessed 30 May 2013.
  29. 29.
    • Zuvekas S, Vitiello B. Stimulant medication use among US children: A twelve-year perspective. Am J Psychiatry. 2012;169(2):160–66. A careful longitudinal study showing a slowing in overall rates of stimulant medication use among US children over the twelve year period, but a worrying increase in use among adolescents.PubMedCrossRefGoogle Scholar
  30. 30.
    INCB. International Narcotics Control Board. Report of the International Narcotics Control Board for 2007. 2007. http://www.incb.org/pdf/annual-report/2007/en/annual-report-2007.pdf
  31. 31.
    Timimi S, Taylor E. ADHD is best understood as a cultural construct. Br J Psychiatry. 2004;184:8–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Moffitt TE, Melchior M. Why does the worldwide prevalence of childhood attention deficit hyperactivity disorder matter? Am J Psychiatry. 2007;164(6):856–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Amaral OB. Psychiatric disorders as social constructs: ADHD as a case in point. Am J Psychiatry. 2007;164:1612–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Bass JK, Bolton PA, Murray LK. Do not forget culture when studying mental health. The Lancet. 2007;370(9591):918–9.CrossRefGoogle Scholar
  35. 35.
    Watters E. Crazy like us: The globalization of the American psyche. New York: Free Press; 2010.Google Scholar
  36. 36.
    Kirmayer L. Beyond the ‘new cross-cultural psychiatry’: Cultural biology, discursive psychology and the ironies of globalization. Transcult Psychiatry. 2006;43(1):126.PubMedCrossRefGoogle Scholar
  37. 37.
    Moynihan R, Doran E, Henry D. Disease mongering is now part of the global health debate. PloS Medicine. 2008;5(5):e106.PubMedCrossRefGoogle Scholar
  38. 38.
    Dumit J. Drugs for Life: How Pharmaceutical Companies Define Our Health. Durham and London: Duke University Press; 2012.Google Scholar
  39. 39.
    Grand Challenges in Global Mental Health Initiative. www.grandchallengesgmh.nimh.nih.gov
  40. 40.
    •• The Lancet. Global Mental Heath. 2011. http://www.thelancet.com/series/global-mental-health-2011 The series is the second of two Lancet special issues that outlines key challenges in global mental health. The series helped mobilize the NIH, WHO and UN to regard mental health in the context of global public health trajectories and goals.
  41. 41.
    The Lancet. Global Mental Heath. 2007. http://www.thelancet.com/series/global-mental-health
  42. 42.
    Summerfield D. Afterword: Against “global mental health”. Transcut Psychiatry. 2012;49(3):1–12. doi:10.1177/1363461512454701.Google Scholar
  43. 43.
    Bemme D, D’Souza N. Global Mental Health and its Discontents. somatosphere.net. 2012. http://somatosphere.net/2012/07/global-mental-health-and-its-discontents.html
  44. 44.
    Farmer P. An Anthropology of Structural Violence. Curr Anthropol. 2004;45(3).Google Scholar
  45. 45.
    Canino G, Alegria M. Psychiatric diagnosis- is it universal or relative to culture? J Child Psychol Psychiatry. 2008;49(3):237–50.PubMedCrossRefGoogle Scholar
  46. 46.
    Wakefield JC, Pottick KJ, Kirk SA. Should the DSM-IV criteria for conduct disorder consider social context? Am J Psychiatry. 2002;159:380–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Rohde LA, Szobot C, Polanczyk G, Schmitz M, Martins S, Tramontina S. Attention-Deficit/Hyperactivity Disorder in a Diverse Culture: Do Research and Clinical Findings Support the Notion of a Cultural Construct for the Disorder? Biol Psychiatry. 2005;57:1436–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Bronfenbrenner U. The ecology of human development. Camridge, MA: Harvard UP; 1979.Google Scholar
  49. 49.
    Merrill RM, Lyon JL, Baker RK, Gren LH. Attention deficit hyperactivity disorder and increased risk of injury. Advanced Medical Science. 2009;54:20–6.Google Scholar
  50. 50.
    Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.PubMedCrossRefGoogle Scholar
  51. 51.
    World Health Organization. Constitution. 1946/2006. http://www.who.int/governance/eb/who_constitution_en.pdf
  52. 52.
    Fulton BD, Scheffler RM, Hinshaw SP, Levine P, Stone S, Brown TT, Modrek S. National Variation of ADHD Diagnostic Prevalence and Medication Use: Health Care Providers and Education Policies. Psychiatr Serv. 2009;60(80).Google Scholar
  53. 53.
    Getahun G, Jacobsen SJ, Fassett MJ, Chen W, Demissie K, Rhoads GG. Recent Trends in Childhood Attention-Deficit/Hyperactivity Disorder. JAMA Pediatr. 2013;167(3):282–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Froehlich TE, Lamphear BP, Epstein JN, Barbesi WJ, Katusic SK, Kahn RS. Prevalence, recognition, and treatment of Attention-Deficit/Hyperactivity Disorder in a national sample of US children. Arch Pediatr Adolesc Med. 2007;161(9):857–64.PubMedCrossRefGoogle Scholar
  55. 55.
    Zima BT, Bussing R, Tang L, Zhang L, Ettner S, Belin TR, et al. Quality of care for childhood attention-deficit/hyperactivity disorder in a managed care Medicaid program. J Am Acad Child Adolesc Psychiatry. 2010;49(12):1225–37.PubMedGoogle Scholar
  56. 56.
    Zito JM, Safer DJ, Devadatta S, Gardner JF, Thomas D, Coombes P, et al. Pediatrics. 2008;121(1):e157–163.PubMedCrossRefGoogle Scholar
  57. 57.
    Morgan PL, Staff J, Hillemeier MM, Farkas G, Maczuga S. Racial and Ethnic Disparities in ADHD Diagnosis From Kindergarten to Eighth Grade. Pediatr. 2013; doi: 10.1542/peds.2012-2390
  58. 58.
    Frazier TW, Shattuck PT, Narendorf SC, Cooper BP, Wagner M, Spiznagel EL. Prevalence and correcolates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21:571–9.PubMedCrossRefGoogle Scholar
  59. 59.
    DosReis S, Barksdale CL, Sherman A, Maloney K, Charach A. Stigmatizing experiences of parents of children with a new diagnosis of ADHD. Psychiatr Serv. 2010;61(8):811–6. doi:10.1176/appi.ps.61.8.811.PubMedCrossRefGoogle Scholar
  60. 60.
    Hinshaw SP, Stier A. Stigma as Related to Mental Disorders. Annu Rev Clin Psychol. 2008;4:367–93. doi:10.1146/annurev.clinpsy.4.022007.141245.PubMedCrossRefGoogle Scholar
  61. 61.
    • Mueller AK, Fuermaier ABM, Koerts J, and Tucha L. Stigma in attention deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2012;4(3):101–114. doi:10.1007/s12402-012-0085-3 DOI:10.1007%2Fs12402-012-0085-3. A key, comprehensive meta-analysis of the stigma literature in ADHD.
  62. 62.
    Singh I. Doing their jobs: Mothering with Ritalin in a culture of mother-blame. Soc Sci Med. 2004;59(6):1193–205.PubMedCrossRefGoogle Scholar
  63. 63.
    Koro-Ljungberg M, Bussing R. The management of courtesy stigma in the lives of families with teenagers with ADHD. J Fam Issues. 2009;30:1175–200.CrossRefGoogle Scholar
  64. 64.
    Frazzetto G, Keenan S, Singh I. Bambini e le droghe: The case of ADHD and Ritalin in Italy. BioSocieties. 2008;2(4):393–412.CrossRefGoogle Scholar
  65. 65.
    O'Driscoll C, Heary C, Hennessy E, McKeague L. Explicit and implicit stigma towards peers with mental health problems in childhood and adolescence. J Child Psychol Psychiatry. 2012;53(10):1054–62. doi:10.1111/j.1469-7610.2012.02580.x.PubMedCrossRefGoogle Scholar
  66. 66.
    Singh I. A disorder of anger and aggression: Children's perspectives on Attention Deficit/Hyperactivity Disorder in the UK. Soc Sci Med. 2011;73:889–96.PubMedCrossRefGoogle Scholar
  67. 67.
    Bröer C, Heerings M. Neurobiology in public and private discourse: the case of adults with ADHD. Sociol Health & Ill. 2013;35(1):49–65.CrossRefGoogle Scholar
  68. 68.
    Filipe AM. Through the looking-glass: a critical review of sociology and medicine towards the diagnosis of ADHD. Configurações. 2011;8:73–86.CrossRefGoogle Scholar
  69. 69.
    Edwards C, Howlett E. Putting knowledge to trial: ‘ADHD parents’ and the evaluation of alternative therapeutic regimes. Soc Sci Med. 2013;81:34–41.PubMedCrossRefGoogle Scholar
  70. 70.
    Edwards C, Howlett E, Akrich M, Rabeharisoa V. Attention deficit hyperactivity disorder in France and Ireland: parents' groups' scientific and political framing of an unsettled condition. 2012. http://www.csi.mines-paristech.fr/working-papers/DLWP.php?wp=WP_CSI_024.pdf. Accessed 30 May 2013.
  71. 71.
    Ortega F. The Cerebral Subject and the Challenge of Neurodiversity. BioSocieties. 2009;4:425–45.CrossRefGoogle Scholar
  72. 72.
    Behague D. Psychiatry and Politics in Pelotas, Brazil: The Equivocal Quality of Conduct Disorder and Related Diagnoses. Med Anthropol Q. 2009;23(4):455–82.PubMedCrossRefGoogle Scholar
  73. 73.
    Wilcox CE, Washburn R, Patel V. Seeking help for attention deficit hyperactivity disorder in developing countries: a study of parental explanatory models in Goa. India Soc Sci Med. 2007;64(8):1600–10.CrossRefGoogle Scholar
  74. 74.
    Bruckner TA, Hodgson A, Mahoney CB, Fulton BD, Levine P, Scheffler RM. Health care supply and county-level variation in attention-deficit hyperactivity disorder prescription medications. Pharmacoepidemiol Drug Saf. 2012;21(4):442–9. doi:10.1002/pds.2264.PubMedCrossRefGoogle Scholar
  75. 75.
    Wang PS, Berglund P, Olfson M, Pincus HA. Wells, Kessler RC. Failure and Delay in Initial Treatment Contact After First Onset of Mental Disorders in the National Comorbidity Survey Replication Arch Gen Psychiatry. 2005;62(6):603–13.Google Scholar
  76. 76.
    Schwarz A. Attention Disorder or Not, Pills to Help in School. The New York Times. 9 October 2012. http://www.nytimes.com/2012/10/09/health/attention-disorder-or-not-children-prescribed-pills-to-help-in-school.html?src=me&ref=general
  77. 77.
    Singh I. Not Robots: Children's perspectives on authenticity, moral agency and stimulant drug treatments. J Med Ethics. 2012. doi:10.1136/medethics-2011-100224.PubMedGoogle Scholar
  78. 78.
    Singh I. VOICES Study: Final Report video clip ‘Doctors’: http://youtu.be/lFyglFDR650
  79. 79.
  80. 80.
    Green JG, Gruber MJ, Kessler RC, Lin JY, McLaughlin MA, Sampson NA, et al. Diagnostic validity across racial and ethnic groups in the assssment of adolescent DSM-IV disorders. Int J Methods Psychiatr Res. 2012;21(14):311–20.PubMedCrossRefGoogle Scholar
  81. 81.
    • Nigg J. Future directions in ADHD etiology research. J Clin Child Adolesc Psychol. 2012;41(4):524–33. Key overview of the importance of specifying environmental and historical contributions to ADHD etiology.PubMedCrossRefGoogle Scholar
  82. 82.
    Frank A. The Wounded Storyteller: Body, Illness, and Ethics. Chicago: University of Chicago Press; 2010.Google Scholar
  83. 83.
    Kleinman A. Rethinking Psychiatry: from cultural category to personal experience. New York: The Free Press; 1988.Google Scholar
  84. 84.
    Good B. Medicine, Rationality, and Experience: An Anthropological Perspective. Cambridge: Cambridge UP; 1994.Google Scholar
  85. 85.
    Singh I, Kelleher KJ. Brain enhancement in children. In: Farah M, Chatterjee A, editors. Neuroethics in Practice. Oxford, UK: Oxford University Press; 2013.Google Scholar
  86. 86.
    Advokat C. What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/hyperactivity disorder (ADHD). Neuroscience & Biobehav Rev. 2010;34(8):1256–66.CrossRefGoogle Scholar
  87. 87.
    Hall WD, Lucke JC. The enhancement use of neuropharmaceuticals: more scepticism and caution needed. Addiction. 2010;105(12):2041–3.PubMedCrossRefGoogle Scholar
  88. 88.
    Repantis D, Schlattmann P, Laisney O, Heuser I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010;62:187–206.PubMedCrossRefGoogle Scholar
  89. 89.
    •• Smith MF, Farah MJ. Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychol Bull. 2011;137(5):717–41. The most authoritative overview to date of the scientific literature on cognitive enhancement, and a meta-analysis of US prevalence estimates.PubMedCrossRefGoogle Scholar
  90. 90.
    Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS. Motives and perceived consequences of nonmedical ADHD medication use by college students are students treating themselves for attention problems? J Atten Disord. 2009;13(3):259–70.PubMedCrossRefGoogle Scholar
  91. 91.
    • Ilieva I, Boland J, Farah MJ. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology. 2012;64(1):496–505. The first systematic investigation of the important question of how perceptions of cognitive enhancement correlate with objectively measurable outcomes.PubMedGoogle Scholar
  92. 92.
    Vrecko S. Just how cognitive is “cognitive enhancement”? On the significance of emotions in university students’ experiences with study drugs. AJOB Neuroscience. 2013;4(1):4–12.PubMedCrossRefGoogle Scholar
  93. 93.
    •• Ragan CI, Bard I, Singh I. What should we do about student use of cognitive enhancers? An analysis of current evidence. Neuropharmacology. 2013;64:588–95. doi:10.1016/j.neuropharm.2012.06.016. Authoritative overview of cross-national prevalence estimates in cognitive enhancement; and an assessment of need for policy intervention.PubMedCrossRefGoogle Scholar
  94. 94.
    Franke AG, Bonertz C, Christmann M, Huss M, Fellgiebel A, Hildt A, et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry. 2010;43:1–7.CrossRefGoogle Scholar
  95. 95.
    Humle T, Friislund M. ‘Study drugs’ vinder frem på universiteter. In: Information Online. 2010. http://www.information.dk/236139.
  96. 96.
    Hansard. HC Deb 4 June 2013, cc1072W-1073W.Google Scholar
  97. 97.
    Italian National Committee for Bioethics (CNB), Presidency of the Council of Ministers. Neuroscience and Pharmacological Cognitive Enhancement: Bioethical Aspects. 2013. http://www.palazzochigi.it/bioetica/eng/opinions/Neuroscience_and_pharmacological_cognitive_enhancement_20130613.pdf
  98. 98.
    Swanson JM, Wigal T, Volkow ND. Contrast of medical and non-medical use of stimulant drugs: Basis for the distinction, and risk of addicition: Comment on Smith and Farah. Psychol Bull. 2011;137(5):742–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Rimsza ME, Moses KS. Substance abuse on the college campus. Pediatr Clin North Am. 2005;52(1):307–19.PubMedCrossRefGoogle Scholar
  100. 100.
    Friedman RA. The Changing Face of Teenage Drug Abuse - The Trend toward Prescription Drugs. N Engl J Med. 2006;354(14):1448–50.PubMedCrossRefGoogle Scholar
  101. 101.
    Schwarz A. Attention-Deficit Drugs Face New Campus Rules. The New York Times. 30 April 2013.Google Scholar
  102. 102.
    Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction. 2012;107(3):467–77.PubMedCrossRefGoogle Scholar
  103. 103.
    Rabiner DL. Stimulant Prescription Cautions: Addressing Misuse. Diversion and Malingering Curr Psychiatry Rep. 2013;15(7):1–8.Google Scholar
  104. 104.
    Talbot M. Can a daily pill really boost your brain power? The Guardian Online. 2009. http://www.guardian.co.uk/science/2009/sep/20/neuroenhancers-us-brain-power-drugs
  105. 105.
    Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. Can Med Assoc J. 2001;1658:1039–44.Google Scholar
  106. 106.
    Garnier-Dykstra LM, Caldeira KM, Vincent KB, O’Grady KE, Arria AM. Nonmedical use of prescription stimulants during college: Four-year trends in exposure opportunity, use, motives, and sources. J Am Coll Health. 2012;60(3):226–34.PubMedCrossRefGoogle Scholar
  107. 107.
    McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use, and diversion of abusable prescription drugs. J Am Coll Health. 2006;54(5):269–78.PubMedCrossRefGoogle Scholar
  108. 108.
    Peterkin AL, Crone CC, Sheridan MJ, Wise TN. Cognitive performance enhancement: Misuse of self-treatment. J Atten Disord. 2010; doi:10.1177/1087054710365980
  109. 109.
    Bostrom N, Sandberg A. Cognitive enhancement: methods, ethics, regulatory challenges. Sci Eng Ethics. 2009;15(3):311–41.PubMedCrossRefGoogle Scholar
  110. 110.
    Harris J. Enhancing Evolution: The Ethical Case for Making Better People. Princeton University Press; 2007Google Scholar
  111. 111.
    Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702–5.PubMedCrossRefGoogle Scholar
  112. 112.
    Larriviere D, Williams MA, Rizzo M, Bonnie RJ. Responding to requests from adult patients for neuroenhancements Guidance of the Ethics. Law and Humanities Committee Neurology. 2009;73(17):1406–12.Google Scholar
  113. 113.
    British Medical Association (BMA). Boosting your Brainpower: Ethical Aspects of Cognitive Enhancement. Report, Nov 2007.Google Scholar
  114. 114.
    CEST. Psychiatric Drugs and Expanded Uses: an Ethical Perspective. 2009. http://www.ethique.gouv.qc.ca/index.php?option=com_docman&Itemid=22&lang=en
  115. 115.
    Singh I, Kelleher KJ. Neuroenhancement in young people: proposal for research, policy and clinical management. Am J Bioeth Neurosci. 2010;1(1):3–16.Google Scholar
  116. 116.
    •• Graf WD, Nagel SK, Epstein LG, Miller G, Nass R, Larriviere D. Pediatric neuroenhancement Ethical, legal, social, and neurodevelopmental implications. Neurology. 2013;80(13):1251–60. First public statement by a professional group (American Academy of Neurology) on pediatric cognitive enhancement.PubMedCrossRefGoogle Scholar
  117. 117.
    Sonuga-Barke EJ, Koerting J, Smith E, McCann DS, Thompson M. Early detection and intervention for attention deficit hyperactivity disorder. Expert Review of Neurotherapeutics. 2011;11(4):557–63.PubMedCrossRefGoogle Scholar
  118. 118.
    Singh I, Sinnott-Armstrong W, Savulescu J. (in press). Bioprediction, Biomarkers, and Bad Behavior: Scientific, Legal, and Ethical Challenges. Oxford UP.Google Scholar
  119. 119.
    Singh I, Rose N. Biomarkers in psychiatry: Promises and perils in the real world. Nature. 2009;460(7252):202–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ilina Singh
    • 1
  • Angela M. Filipe
    • 1
  • Imre Bard
    • 2
  • Meredith Bergey
    • 3
  • Lauren Baker
    • 1
  1. 1.Department of Social Science, Health & MedicineKing’s College LondonLondonUK
  2. 2.Methodology DepartmentLondon School of Economics & Political ScienceLondonUK
  3. 3.Sociology DepartmentBrandeis UniversityWalthamUSA

Personalised recommendations